Search

Your search keyword '"Okazaki, Toshihiko"' showing total 123 results

Search Constraints

Start Over You searched for: Author "Okazaki, Toshihiko" Remove constraint Author: "Okazaki, Toshihiko"
123 results on '"Okazaki, Toshihiko"'

Search Results

1. Data from TLR7 Ligand Augments GM-CSF–Initiated Antitumor Immunity through Activation of Plasmacytoid Dendritic Cells

2. ntary Methods, Figure Legends from TLR7 Ligand Augments GM-CSF–Initiated Antitumor Immunity through Activation of Plasmacytoid Dendritic Cells

3. Supplementary Figures 1 - 7 from TLR7 Ligand Augments GM-CSF–Initiated Antitumor Immunity through Activation of Plasmacytoid Dendritic Cells

4. Supplementary Figure 5 from Coxsackievirus B3 Is an Oncolytic Virus with Immunostimulatory Properties That Is Active against Lung Adenocarcinoma

5. Data from Coxsackievirus B3 Is an Oncolytic Virus with Immunostimulatory Properties That Is Active against Lung Adenocarcinoma

6. Supplementary Figure 2 from Coxsackievirus B3 Is an Oncolytic Virus with Immunostimulatory Properties That Is Active against Lung Adenocarcinoma

7. Supplementary Figure 1 from Coxsackievirus B3 Is an Oncolytic Virus with Immunostimulatory Properties That Is Active against Lung Adenocarcinoma

8. Supplementary Figure 3 from Coxsackievirus B3 Is an Oncolytic Virus with Immunostimulatory Properties That Is Active against Lung Adenocarcinoma

9. Supplementary Figure 4 from Coxsackievirus B3 Is an Oncolytic Virus with Immunostimulatory Properties That Is Active against Lung Adenocarcinoma

10. Supplementary Figure Legends 1-5 from Coxsackievirus B3 Is an Oncolytic Virus with Immunostimulatory Properties That Is Active against Lung Adenocarcinoma

11. Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors

15. NFKB1 promoter variation implicates shear-induced NOS3 gene expression and endothelial function in prehypertensives and stage I hypertensives

19. A Novel Combination Therapy for Human Oxaliplatin-resistant Colorectal Cancer Using Oxaliplatin and Coxsackievirus A11

21. A phase I clinical trial of RNF43 peptide-related immune cell therapy combined with low-dose cyclophosphamide in patients with advanced solid tumors

25. Contribution of higher risk genes and European admixture to Crohnʼs disease in African Americans

26. 631. Novel Polymer-Coated Stealth Oncolytic Measles Virus Overcame Immune Suppression and Induced Stronger Antitumor Activity

27. Newly Developed Measles Viral Vector Can Efficiently Transduce Multiple Genes into naïve T Cells

30. Immune and Gene Therapy as an Emerging Cancer Treatment

31. TLR7 Ligand Augments GM-CSF–Initiated Antitumor Immunity through Activation of Plasmacytoid Dendritic Cells

32. Critical Role of AZI2 in GM-CSF–Induced Dendritic Cell Differentiation

33. Contribution of higher risk genes and European admixture to Crohnʼs disease in African Americans

34. Coxsackievirus B3 Is an Oncolytic Virus with Immunostimulatory Properties That Is Active against Lung Adenocarcinoma

36. The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection

37. Enhanced Antitumor Effects of an Engineered Measles Virus Edmonston Strain Expressing the Wild-type N, P, L Genes on Human Renal Cell Carcinoma

38. 202 In African Americans, NOD2, SLC22A5 and ATG16L1 But Not Il23R or IRGM Are Genetic Risk Factors for Crohn's Disease

46. A novel NFKB1 promoter polymorphism shows altered binding to nuclear proteins and increases risk for ulcerative colitis

Catalog

Books, media, physical & digital resources